An FDA committee's vote to allow compounding pharmacies to create certain peptides is not about approving them as effective drugs. It's a pragmatic move to provide a safer, domestically-produced alternative for people already buying these substances from unregulated international or "gray" markets, aiming to improve safety.
The six peptides under FDA consideration are "naked," lacking the chemical enhancements of modern peptide drugs like GLP-1s. This simple structure causes them to break down very quickly in the body, likely before they can produce any meaningful biological effect, rendering them potentially expensive placebos.
Instead of digital screening, Sethera Therapeutics generates vast physical libraries of hundreds of trillions of unique peptides within a small test tube. Each peptide is given a unique barcode, enabling researchers to test them against real biological targets and identify effective molecules from infinitesimally small quantities.
Sethera's approach to triple-negative breast cancer doesn't just kill cancer cells but aims to "decancerify" them. A custom peptide interacts with a key mutated protein, restoring its natural, non-cancerous state. This reversion triggers the cell's innate biology to initiate self-destruction, offering a highly targeted therapy.
Enzymes are used like modular building blocks to enhance peptides beyond simply altering their shape for a specific function. Different enzymes can be applied to solve other drug development challenges, such as increasing a peptide's stability and longevity in the body or enabling it to penetrate target cells.